



## NOTE

Virology

# Investigation of multiple *Felis catus* papillomavirus types (-1/-2/-3/-4/-5/-6) DNAs in feline oral squamous cell carcinoma: a multicentric study

Gennaro ALTAMURA<sup>1)</sup>, Bianca CUCCARO<sup>1)</sup>, Claudia ELEN<sup>2)</sup>,  
Carina STROHMAYER<sup>3)</sup>, Sabine BRANDT<sup>3)</sup> and Giuseppe BORZACCHIELLO<sup>1)\*</sup>

<sup>1)</sup>Department of Veterinary Medicine and Animal Productions, University of Naples Federico II, Naples, Italy

<sup>2)</sup>Istituto Zooprofilattico Sperimentale del Lazio e della Toscana 'M. Aleandri', Rome, Italy

<sup>3)</sup>University Equine Clinic, University of Veterinary Medicine, Wien, Austria

*J. Vet. Med. Sci.*

84(6): 881–884, 2022

doi: 10.1292/jvms.22-0060

Received: 14 February 2022

Accepted: 3 April 2022

Advanced Epub:

15 April 2022

**ABSTRACT.** Recent evidence suggests a possible association of *Felis catus* papillomavirus type 2 (FcaPV-2) DNA with feline oral squamous cell carcinoma (FOSCC). In this study, type-specific PCR targeting two genes (L1/E6 or E1/E6) of FcaPV-1/-2/-3/-4/-5/-6 was performed to detect viral DNA in a large amount of FOSCC samples collected in Italy and Austria. FcaPV-1/-2/-3/-4/-5 were detected in 7/113 (6.2%), 7/93 (7.5%), 6/113 (5.3%), 1/113 (0.9%) and 2/113 (1.8%) specimens, respectively, with different prevalences in Italian vs. Austrian samples, whilst FcaPV-6 went undetected. Our results confirms that FcaPV-2 is the most prevalent in FOSCC, followed by FcaPV-1/-3 and suggest that FcaPVs have variable circulation rates in European countries.

**KEYWORDS:** cat, *Felis catus* papillomavirus, oral squamous cell carcinoma, PCR

Papillomaviruses (PV) are oncogenic viruses that infect cutaneous and mucosal epithelia in human and animal species, causing development of proliferative lesions ranging from warts to squamous cell carcinoma (SCC) [17].

In domestic cat (*Felis catus*), six FcaPV types (-1/-2/-3/-4/-5/-6) have been characterized, so far [17]. FcaPV-2 is recognized as the causative agent of cutaneous SCC and its precursors, since it is widely detectable and transcriptionally active in tumor samples and displays transforming properties *in vitro* through the molecular activities of its E6/E7 oncogenes [2, 4, 26]. Alongside FcaPV-2, FcaPV-1/-3/-4/-5/-6 are rarely associated with skin lesions, however their role in cancer development is not fully understood [8, 10, 14, 23, 27, 30].

In humans, 20–25% of oral SCCs are causally associated with infection by Human PV-16 (HPV-16), whilst in cats the possible association between PV infection and oral cancer is still debated [17, 24]. Indeed, most of the studies, based on consensus PCR on formalin-fixed paraffin-embedded (FFPE) tissues, yielded scarce to null detection of viral sequences in feline oral SCC (FOSCC) [18, 21, 22]. However, our recent work pointed out that the use of type-specific primers amplifying short sequences increased PCR performance, leading to detection of FcaPV-2 in 10/32 (31%) FOSCC samples in Italy [6]. Moreover, studies conducted with similar methods in Japan found FcaPV-2 in 12/28 (42.9%) tumors, strengthening the possibility of a biologically significant association [29].

The aim of this work was to assess, by using the appropriate PCR strategy, the presence of FcaPV-1/-2/-3/-4/-5/-6 in a large cohort of FOSCC samples collected in two different countries (Italy and Austria), in order to obtain a reliable estimation of their possible association with these tumors.

To this purpose, a total of 113 FFPE-FOSCC samples (T1–T113) were collected: samples T1–T32 (32/113) were retrieved from the archives of the “Istituto Zooprofilattico Sperimentale del Lazio e della Toscana ‘M. Aleandri’”, Rome, Italy (years 2013–2020). Of these, 20/32 (T1–T19, T32) belonged to the cohort of samples analyzed for the presence of FcaPV-2 in our previous work and 9/20 had tested positive (T2–T7, T10–T11, T32) [6]; samples T33–T113 (81/113) were retrieved from the archive of the Research Group Oncology (RGO) or the Institute of Pathology of the University of Veterinary Medicine, Wien, Austria (years 2001–2019). All the samples were from household cats; the ages of 100 affected cats were known, ranging from 5 to 19 years

\*Correspondence to: Borzacchiello, G.: borzacch@unina.it, Department of Veterinary Medicine and Animal Productions, University of Naples Federico II, Via Delpino 1, 80137, Naples, Italy

(Supplementary material: refer to PMC <https://www.ncbi.nlm.nih.gov/pmc/journals/2350/>)

©2022 The Japanese Society of Veterinary Science



This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: <https://creativecommons.org/licenses/by-nc-nd/4.0/>)

(mean 13.27). Sections of 5/10 µm thickness were cut with separate microtome blades and stored in sterile tubes for subsequent molecular analysis. Additionally, 3 FOSCC cell lines (SCCF1 and FcaPV-2 positive SCCF2 and SCCF3), cultured as indicated in literature, were included in the study [5, 12, 13, 25].

DNA extraction and PCR reactions were performed as previously described [6]. The quality of DNA samples was ensured by PCR for feline β-globin or β-actin as reported elsewhere [3, 7]. Amplification of FcaPV-1 E1 and FcaPV-2/-3/-4 L1 was carried out by employing the validated type-specific primer pairs FVP1F/R, JMPF/R, JMY2F/R, JMY3F/R, respectively, whilst new primers amplifying FcaPV-5/-6 L1 were designed for this study [16, 19, 20]. PCR for FcaPV-2 E6 was performed as previously described, additional primer pairs were synthesized to specifically amplify E6 from FcaPV-1/-3/-4/-5/-6 [4]. Primers details including names, sequences, annealing temperatures and intended product sizes are summarized in [Supplementary Table 1](#). For each PCR reaction, samples with no DNA template were included as negative control. Cloned FcaPV-1 and FcaPV-2 genomes, DNA from an FcaPV-3 positive SCC, gBlocks Gene Fragments (Integrated DNA Technologies, Coralville, IA, USA) mimicking the FcaPV-4/-5/-6 L1 and E6 intended amplicons were employed as positive controls. PCR products were visualized by agarose gel electrophoresis and UV light as previously described [6]. Randomly chosen amplicons from E6 PCR were purified by using QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) and submitted to sequence analysis (BMR-Genomics, Padova, Italy). The obtained sequences were aligned to viral genes using the Basic Local Alignment Search Tool (NCBI/BLAST). FOSCC samples and cell lines were tested for the presence of viral DNAs by amplifying two genes of each viral type, such as E1/E6 for FcaPV-1 and L1/E6 for FcaPV-2/-3/-4/-5/-6; samples T103-T113 could be analyzed only for E6, T32 only for E1/L1. For a comprehensive view of PCR results, see [Table 1](#).

FcaPV-1 was detected in 7/113 (6.2%) FOSCC samples, of these 1/113 (0.9%) was positive only for E1 (T39), 6/113 (5.3%) only for E6 (T34, T48, T61, T64, T74, T103). In the case of FcaPV-2, 20/113 samples (T1-T19, T32), accounting for most of Italian cohort (20/32), were neither analyzed nor included in the prevalence rates, given their belonging to data already published in our previous study [6]. Among the rest of the samples, 7/93 (7.5%) tested positive for FcaPV-2 DNA, of which 3/93 (3.2%) for L1 (T37, T39, T42), 5/93 (5.4%) for E6 (T39, T85, T93, T102, T112), 1/93 (1.3%) for both genes. FcaPV-3 was detected in 6/113 (5.3%) FOSCC samples, of these 5/113 (4.4%) were positive for L1 (T4, T32, T38, T52, T63), 4/113 (3.5%) for E6 (T3, T4, T38, T63), 3/113 (2.6%) were double-positive. FcaPV-4 and FcaPV-5 DNAs were amplified in 1/113 (0.9%; T66) and 2/113 (1.8%; T22, T28) samples, respectively, solely by L1 PCR. FcaPV-6 was not found in any of the analyzed specimens. Four co-infections could be evidenced: T39 was positive for FcaPV-1/-2, three FcaPV-3 positive FOSCCs (T3, T4, T32) were known to harbor also FcaPV-2 from Altamura *et al.*, 2020 [6]. Sequencing of randomly chosen E6 PCR products confirmed the identity of the amplicons. Representative PCR gels are shown in [Supplementary Figs. 1 and 2](#). There was no difference in the age between PV-positive and negative cases.

When splitting results according to geographical area ([Table 2](#)), it came out that in Austrian samples FcaPV-1 and -2 shared the highest prevalence (7/81, 8.6% for both), followed by FcaPV-3 (3/81, 3.7%) and -4 (1/81, 1.2%), whilst FcaPV-5 went undetected. In samples from Italy, FcaPV-1/-4 were not found, whilst FcaPV-3 and -5 were revealed with a prevalence of 9.3% (3/32) and 6.2% (2/32), respectively. Negative FcaPV-2 PCR results (0/12) and thus null prevalence in Italian samples analyzed *ex novo* in this study (12/32) were not deemed to be representative due to the small sample size, therefore they were not further considered throughout the manuscript.

No viral DNA was amplifiable in SCCF1, and no additional viral types were detected in FcaPV-2 positive SCCF2/3 cell lines.

This is the first study specifically testing the presence of each FcaPV type in such a numerous sample of FOSCC and cell lines. A possible limitation may be DNA fragmentation occurring in FFPE samples, which might have influenced PCR results; however,

**Table 1.** Detection of *Felis catus* papillomavirus (FcaPV) type -1/-2/-3/-4/-5 in feline oral squamous cell carcinoma by PCR

|          | FcaPV-1      |              |            | FcaPV-2     |             |             | FcaPV-3      |              |              | FcaPV-4      |            |            | FcaPV-5      |            |            | FcaPV-6    |            |            |
|----------|--------------|--------------|------------|-------------|-------------|-------------|--------------|--------------|--------------|--------------|------------|------------|--------------|------------|------------|------------|------------|------------|
|          | E1           | E6           | E1/E6      | L1          | E6          | L1/E6       | L1           | E6           | L1/E6        | L1           | E6         | L1/E6      | L1           | E6         | L1/E6      | L1         | E6         | L1/E6      |
| Per gene | 1/113 (0.9%) | 6/113 (5.3%) | 0/113 (0%) | 3/93 (3.2%) | 5/93 (5.4%) | 1/93 (1.3%) | 5/113 (4.4%) | 4/113 (3.5%) | 3/113 (2.6%) | 1/113 (0.9%) | 0/113 (0%) | 0/113 (0%) | 2/113 (1.8%) | 0/113 (0%) | 0/113 (0%) | 0/113 (0%) | 0/113 (0%) | 0/113 (0%) |
| Total    | 7/113 (6.2%) |              |            | 7/93 (7.5%) |             |             | 6/113 (5.3%) |              |              | 1/113 (0.9%) |            |            | 2/113 (1.8%) |            |            | 0/113 (0%) |            |            |

For each viral type, single-positive (E1 or L1 and E6), double-positive (E1/E6 and L1/E6) and total PCR positive ratios (%) are indicated.

**Table 2.** PCR positive ratios (%) for each *Felis catus* papillomavirus (FcaPV) type splitted according to geographical area of feline oral squamous cell carcinoma (FOSCC) sampling (Italy vs. Austria)

|               | FcaPV-1     | FcaPV-2     | FcaPV-3     | FcaPV-4     | FcaPV-5     | FcaPV-6   |
|---------------|-------------|-------------|-------------|-------------|-------------|-----------|
| FOSCC Italy   | 0/32 (0%)   | 0/12 (0%)   | 3/32 (9.3%) | 0/32 (0%)   | 2/32 (6.2%) | 0/32 (0%) |
| FOSCC Austria | 7/81 (8.6%) | 7/81 (8.6%) | 3/81 (3.7%) | 1/81 (1.2%) | 0/81 (0%)   | 0/81 (0%) |

in agreement with previous studies, our data confirm that the use of type-specific primers amplifying short viral sequences allows detection of FcaPVs in FFPE-FOSCCs, likely overcoming this issue and ensuring a better yield with respect to consensus oligos amplifying longer sequences [6, 18, 21, 22, 29]. FcaPV-2 was found to be the most prevalent and confirmed as the unique viral type associated with SCCF2/3 cell lines [5]. These data are in line with the growing evidence supporting a role for FcaPV-2 in development of a subset of FOSCC, such as detection of viral DNA and transcriptional activity in tumor samples and its biological similarities with mucosal HPV-16 in experimental models [4, 5, 26, 29]; nevertheless, FcaPV-2-associated FOSCC has been proposed as a spontaneous animal model of human counterpart [1].

Here we also report, to a lesser extent, detection of FcaPV-1 (6.2%) and FcaPV-3 (5.3%). Our results seem to corroborate some previous studies that reported the presence of FcaPV-1 in 1/36 FOSCC via PCR and FcaPV-3 in 1/20 samples via virome sequencing approach [9, 16]. Additional epidemiological and experimental studies are warranted to eventually confirm whether these two FcaPV types may be a possible rare “cause” of FOSCC. In contrast, prevalence data on FcaPV-4/-5 (0.9%/1.8%) revealed sporadic detection of unlikely biological meaning in FOSCC.

In co-infections, FcaPV-1 or FcaPV-3 were always co-detected along with FcaPV-2, therefore it is likely that this latter plays a major role; however, recent studies suggest that the “causative” agent in skin lesions associated with multiple FcaPVs is identifiable by a higher viral load [14, 27]. Future studies would clarify whether this scenario is conceivable in FOSCC as well.

Interestingly, E6 PCR greatly increased the positive ratios with respect to E1 for FcaPV-1. Studies in human and animal species suggest that this may be due to PV integration into host genome, leading to disruption of E1 gene and thus resulting in loss of some PCR positivity [11, 15]; similarly, the occurrence of E6 single-positive samples for other viral types might be related to integration events which interrupts L genes [28]; however, viral kinetics of FcaPVs are currently unknown, therefore further investigations are needed to clarify this point.

A recent report from Asian countries suggests that the rate of detection of FcaPV-2 in FOSCC may vary according to its general prevalence in a given geographical area; indeed, authors found it in 11/19 tumors from Taiwan vs. 1/9 samples from Japan, where in fact FcaPV-3 and -4 are more prevalent [29, 30]. Consistently, when pooling data on FcaPV-1/-3/-4/-5 obtained in the current study (0/32, 3/32, 0/32, 2/32, respectively) with those on FcaPV-2 from our recent work (10/32), this latter appeared as the most frequently detectable in FOSCC from Italy, in agreement with previous studies reporting FcaPV-2 as highly prevalent over all viral types in this country [6, 14, 27]. Therefore, it is likely that the different detection rates of each FcaPV in Austrian samples compared with Italian ones might be representative of diverse general prevalences. However, the possibility that the different sizes of samples groups (81 vs. 32) may have influenced some results should be taken into account. Finally, this work hints that FcaPV-6, originally isolated in Australia, would be neither circulating in Austria nor in Italy and/or would not exert mucosal tropism [8].

In conclusion, this study confirms that type-specific PCR allows detection of FcaPV-2 and, to a lesser extent, of FcaPV-1/-3 in a subset of FOSCC, thus encouraging further work aimed at unveiling their possible role in oral carcinogenesis and reveals that differences in the prevalence of each viral type may exist among European countries.

**CONFLICT OF INTEREST.** The authors declare that they have no conflict of interest.

**ACKNOWLEDGMENTS.** The authors wish to express their gratitude to Professor T.J. Rosol (The Ohio State University, Department of Veterinary Biosciences, College of Veterinary Medicine, Columbus, Ohio, USA) for his kind gift of SCCF1, SCCF2 and SCCF3 cell lines. Professor A. Rector and M. Van Ranst (Laboratory of Clinical and Epidemiological Virology—Department of Microbiology and Immunology—Rega Institute for Medical Research University of Leuven—Belgium) and Dr. C.E. Lange (The University of Zurich, Vetsuisse Faculty, Institute of Virology, Zurich, Switzerland) are also kindly acknowledged for their kind gifts of cloned FcaPV-1 and FcaPV-2 genomes, respectively. This work was financially supported by a grant from the Board of Directors, University of Naples Federico II.

## REFERENCES

1. Altamura, G. and Borzacchiello, G. 2019. HPV related head and neck squamous cell carcinoma: New evidences for an emerging spontaneous animal model. *Oral Oncol.* **88**: 84. [Medline] [CrossRef]
2. Altamura, G., Corteggio, A. and Borzacchiello, G. 2016. Felis catus papillomavirus type 2 E6 oncogene enhances mitogen-activated protein kinases and Akt activation but not EGFR expression in an in vitro feline model of viral pathogenesis. *Vet. Microbiol.* **195**: 96–100. [Medline] [CrossRef]
3. Altamura, G., Jebara, G., Cardeti, G. and Borzacchiello, G. 2018. Felis catus papillomavirus type-2 but not type-1 is detectable and transcriptionally active in the blood of healthy cats. *Transbound. Emerg. Dis.* **65**: 497–503. [Medline] [CrossRef]
4. Altamura, G., Corteggio, A., Pacini, L., Conte, A., Pierantoni, G. M., Tommasino, M., Accardi, R. and Borzacchiello, G. 2016. Transforming properties of Felis catus papillomavirus type 2 E6 and E7 putative oncogenes in vitro and their transcriptional activity in feline squamous cell carcinoma in vivo. *Virology* **496**: 1–8. [Medline] [CrossRef]
5. Altamura, G., Power, K., Martano, M., Degli Uberti, B., Galiero, G., De Luca, G., Maiolino, P. and Borzacchiello, G. 2018. Felis catus papillomavirus type-2 E6 binds to E6AP, promotes E6AP/p53 binding and enhances p53 proteasomal degradation. *Sci. Rep.* **8**: 17529. [Medline] [CrossRef]
6. Altamura, G., Cardeti, G., Cersini, A., Eleni, C., Cocumelli, C., Bartolomé Del Pino, L. E., Razzuoli, E., Martano, M., Maiolino, P. and Borzacchiello, G. 2020. Detection of Felis catus papillomavirus type-2 DNA and viral gene expression suggest active infection in feline oral squamous cell carcinoma. *Vet. Comp. Oncol.* **18**: 494–501. [Medline] [CrossRef]
7. Brandt, S., Haralambus, R., Schoster, A., Kimbauer, R. and Stanek, C. 2008. Peripheral blood mononuclear cells represent a reservoir of bovine papillomavirus DNA in sarcoid-affected equines. *J. Gen. Virol.* **89**: 1390–1395. [Medline] [CrossRef]

8. Carrai, M., Van Brussel, K., Shi, M., Li, C. X., Chang, W. S., Munday, J. S., Voss, K., McLuckie, A., Taylor, D., Laws, A., Holmes, E. C., Barrs, V. R. and Beatty, J. A. 2020. Identification of a novel papillomavirus associated with squamous cell carcinoma in a domestic cat. *Viruses* **12**: 12. [\[Medline\]](#) [\[CrossRef\]](#)
9. Chu, S., Wylie, T. N., Wylie, K. M., Johnson, G. C., Skidmore, Z. L., Fleer, M., Griffith, O. L. and Bryan, J. N. 2020. A virome sequencing approach to feline oral squamous cell carcinoma to evaluate viral causative factors. *Vet. Microbiol.* **240**: 108491. [\[Medline\]](#) [\[CrossRef\]](#)
10. Kok, M. K., Yamashita-Kawanishi, N., Chambers, J. K., Haritani, M., Ushigusa, T., Haga, T., Nakayama, H. and Uchida, K. 2019. Pathologic characterization of *Felis catus* papillomavirus type 5 (FcpPV-5)-associated viral plaques and Bowenoid in situ carcinoma in a Domestic Shorthair cat. *J. Vet. Med. Sci.* **81**: 660–666. [\[Medline\]](#) [\[CrossRef\]](#)
11. Luff, J., Mader, M., Rowland, P., Britton, M., Fass, J. and Yuan, H. 2019. Viral genome integration of canine papillomavirus 16. *Papillomavirus Res.* **7**: 88–96. [\[Medline\]](#) [\[CrossRef\]](#)
12. Martin, C. K., Werbeck, J. L., Thudi, N. K., Lanigan, L. G., Wolfe, T. D., Toribio, R. E. and Rosol, T. J. 2010. Zoledronic acid reduces bone loss and tumor growth in an orthotopic xenograft model of osteolytic oral squamous cell carcinoma. *Cancer Res.* **70**: 8607–8616. [\[Medline\]](#) [\[CrossRef\]](#)
13. Martin, C. K., Dirksen, W. P., Shu, S. T., Werbeck, J. L., Thudi, N. K., Yamaguchi, M., Wolfe, T. D., Heller, K. N. and Rosol, T. J. 2012. Characterization of bone resorption in novel in vitro and in vivo models of oral squamous cell carcinoma. *Oral Oncol.* **48**: 491–499. [\[Medline\]](#) [\[CrossRef\]](#)
14. Mazzei, M., Forzan, M., Carlucci, V., Anfossi, A. G., Alberti, A., Albanese, F., Binanti, D., Millanta, F., Baroncini, L., Pirone, A. and Abramo, F. 2018. A study of multiple *Felis catus* papillomavirus types (1, 2, 3, 4) in cat skin lesions in Italy by quantitative PCR. *J. Feline Med. Surg.* **20**: 772–779. [\[Medline\]](#) [\[CrossRef\]](#)
15. McBride, A. A. and Warburton, A. 2017. The role of integration in oncogenic progression of HPV-associated cancers. *PLoS Pathog.* **13**: e1006211. [\[Medline\]](#) [\[CrossRef\]](#)
16. Munday, J. S. and French, A. F. 2015. *Felis catus* papillomavirus types 1 and 4 are rarely present in neoplastic and inflammatory oral lesions of cats. *Res. Vet. Sci.* **100**: 220–222. [\[Medline\]](#) [\[CrossRef\]](#)
17. Munday, J. S. and Thomson, N. A. 2021. Papillomaviruses in domestic cats. *Viruses* **13**: 13. [\[Medline\]](#) [\[CrossRef\]](#)
18. Munday, J. S., Knight, C. G. and French, A. F. 2011. Evaluation of feline oral squamous cell carcinomas for p16CDKN2A protein immunoreactivity and the presence of papillomaviral DNA. *Res. Vet. Sci.* **90**: 280–283. [\[Medline\]](#) [\[CrossRef\]](#)
19. Munday, J. S., Gibson, I. and French, A. F. 2011. Papillomaviral DNA and increased p16CDKN2A protein are frequently present within feline cutaneous squamous cell carcinomas in ultraviolet-protected skin. *Vet. Dermatol.* **22**: 360–366. [\[Medline\]](#) [\[CrossRef\]](#)
20. Munday, J. S., Kiupel, M., French, A. F. and Howe, L. 2008. Amplification of papillomaviral DNA sequences from a high proportion of feline cutaneous in situ and invasive squamous cell carcinomas using a nested polymerase chain reaction. *Vet. Dermatol.* **19**: 259–263. [\[Medline\]](#) [\[CrossRef\]](#)
21. Munday, J. S., He, Y., Aberdein, D. and Klobukowska, H. J. 2019. Increased p16<sup>CDKN2A</sup>, but not p53, immunostaining is predictive of longer survival time in cats with oral squamous cell carcinomas. *Vet. J.* **248**: 64–70. [\[Medline\]](#) [\[CrossRef\]](#)
22. Munday, J. S., Howe, L., French, A., Squires, R. A. and Sugiarto, H. 2009. Detection of papillomaviral DNA sequences in a feline oral squamous cell carcinoma. *Res. Vet. Sci.* **86**: 359–361. [\[Medline\]](#) [\[CrossRef\]](#)
23. Munday, J. S., Thomson, N. A., Henderson, G., Fairley, R. and Orbell, G. M. 2018. Identification of *Felis catus* papillomavirus 3 in skin neoplasms from four cats. *J. Vet. Diagn. Invest.* **30**: 324–328. [\[Medline\]](#) [\[CrossRef\]](#)
24. Tanaka, T. I. and Alawi, F. 2018. Human papillomavirus and oropharyngeal cancer. *Dent. Clin. North Am.* **62**: 111–120. [\[Medline\]](#) [\[CrossRef\]](#)
25. Tannehill-Gregg, S., Kergosien, E. and Rosol, T. J. 2001. Feline head and neck squamous cell carcinoma cell line: characterization, production of parathyroid hormone-related protein, and regulation by transforming growth factor-beta. *In Vitro Cell. Dev. Biol. Anim.* **37**: 676–683. [\[Medline\]](#) [\[CrossRef\]](#)
26. Thomson, N. A., Munday, J. S. and Dittmer, K. E. 2016. Frequent detection of transcriptionally active *Felis catus* papillomavirus 2 in feline cutaneous squamous cell carcinomas. *J. Gen. Virol.* **97**: 1189–1197. [\[Medline\]](#) [\[CrossRef\]](#)
27. Vascellari, M., Mazzei, M., Zanardello, C., Melchioti, E., Albanese, F., Forzan, M., Croce, M. F., Alberti, A. and Abramo, F. 2019. *Felis catus* papillomavirus types 1, 2, 3, 4, and 5 in feline bowenoid in situ carcinoma: an in situ hybridization study. *Vet. Pathol.* **56**: 818–825. [\[Medline\]](#) [\[CrossRef\]](#)
28. Xing, B., Guo, J., Sheng, Y., Wu, G. and Zhao, Y. 2021. Human papillomavirus-negative cervical cancer: a comprehensive review. *Front. Oncol.* **10**: 606335. [\[Medline\]](#) [\[CrossRef\]](#)
29. Yamashita-Kawanishi, N., Chang, C. Y., Chambers, J. K., Uchida, K., Sugiura, K., Kukimoto, I., Chang, H. W. and Haga, T. 2021. Comparison of prevalence of *Felis catus* papillomavirus type 2 in squamous cell carcinomas in cats between Taiwan and Japan. *J. Vet. Med. Sci.* **83**: 1229–1233. [\[Medline\]](#) [\[CrossRef\]](#)
30. Yamashita-Kawanishi, N., Sawanobori, R., Matsumiya, K., Uema, A., Chambers, J. K., Uchida, K., Shimakura, H., Tsuzuki, M., Chang, C. Y., Chang, H. W. and Haga, T. 2018. Detection of *Felis catus* papillomavirus type 3 and 4 DNA from squamous cell carcinoma cases of cats in Japan. *J. Vet. Med. Sci.* **80**: 1236–1240. [\[Medline\]](#) [\[CrossRef\]](#)